Share on StockTwits

Research analysts at Oppenheimer started coverage on shares of Xencor (NASDAQ:XNCR) in a report released on Thursday, reports. The firm set an “outperform” rating on the stock.

Xencor (NASDAQ:XNCR) traded down 2.42% on Thursday, hitting $10.08. 68,146 shares of the company’s stock traded hands. Xencor has a 52 week low of $5.75 and a 52 week high of $14.41. The stock’s 50-day moving average is $10.17 and its 200-day moving average is $10.12. The company’s market cap is $316.1 million.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.12) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.16) by $0.04. The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $1.71 million. Analysts expect that Xencor will post $-0.77 EPS for the current fiscal year.

Xencor, Inc (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.